BRIGHT MINDS BIOSCIENCES INC.
corporate_fare Company Profile
BRIGHT MINDS BIOSCIENCES INC. (NASDAQ:DRUG) is a publicly traded company in the Life Sciences sector. Wiseek has independently scored 12 items for DRUG at importance 7 or higher on its 1–10 market-impact scale. Its most recent item scored 7 or higher is dated 2026-05-19, rated 9/10. Across its 12 most recent items scored 7 or higher, the top rating is 9/10, with 11 rated 8 or above. Recent SEC coverage for DRUG spans 6-K, 424B5, FWP.
Recent high-impact activity:
- Bright Minds Biosciences Reports Positive Phase 2 BMB-101 Data & Secures $257M Capital for Pipeline Advancement
- Bright Minds Biosciences Closes $175M Public Offering at Premium to Market Price
- Bright Minds Biosciences Secures $175M Public Offering to Fund Clinical Trials
- Bright Minds Biosciences Announces $175M Public Offering to Fund Clinical Trials
- Bright Minds Biosciences Prices Upsized $175M Public Offering at Small Discount
Financial Snapshot
Short Interest & Short Volume
12.00 days to coverFINRA reported short interest of 931,941 shares in DRUG as of the September 15, 2026 settlement, a 4.3% increase from the prior period — about 12.0 days to cover at its recent average daily volume. On October 2, 2026, 41.7% of DRUG volume reported to FINRA trade-reporting facilities was marked short.
Daily short sale volume covers trades reported to FINRA trade-reporting facilities and is not the same as short interest (bi-monthly reported positions). Source: FINRA — FINRA is the owner and source of this short interest and short sale volume data; it may not be redistributed.
Insider Transactions
DRUG files as a Foreign Private Issuer (FPI). Under SEC Exchange Act Section 16(a), officers, directors, and 10% owners of FPIs are exempt from Form 4 insider-transaction reporting requirements. Comparable disclosures, when applicable, appear in the company's Form 20-F (annual) or Form 6-K (interim) filings on SEC EDGAR.